UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2010

Commission File Number: 001-33340

TONGJITANG CHINESE MEDICINES COMPANY

5th Floor, Block B
Nanshan Medical Device Park
1019 Nanhai Avenue, Shekou, Nanshan District
Shenzhen, 518067 Guangdong Province
People’s Republic of China
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under the cover of Form 20-F or Form 40-F:

Form 20-F þ Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Tongjitang Chinese Medicines Company By: /s/ Xiaochun Wang Name: Xiaochun Wang Title: Chairman and Chief Executive Officer


	Tongjitang Chinese Medicines Company
	By:	/s/ Charles Wang
	Name:	Charles Wang
	Title:	Chief Financial Officer
Date: September 28, 2010

~~Date: September 10, 2010~~2

EXHIBIT INDEX


Exhibit No.				Description
99.1				Press Release

Exhibit 99.1

Tongjitang Chinese Medicines Company ~~Announces~~Enters ~~Resignation of CFO,~~into ~~Effective~~Share ~~December 2,~~Transfer ~~2010~~Agreement

~~SHENZHEN, China, September 8, 2010 (BUSINESS WIRE)~~ — ~~Tongjitang~~Sale ~~Chinese Medicines Company (the “Company” or “Tongjitang”) (NYSE: TCM), a leading specialty pharmaceutical company focusing on the development, manufacturing, marketing and selling~~ of ~~modernized~~Non-Core ~~traditional~~Operating ~~Chinese~~Segment ~~medicine~~Allows ~~in China,~~Greater ~~today~~Focus ~~announced that~~ on ~~September 3,~~Core ~~2010,~~Pharmaceutical ~~Mr. Charles~~Business ~~Wang submitted his resignation as~~— Chief Financial Officer for personal reasons and not as a result of any disagreement with the Company regarding financial or accounting practices. The resignation will be effective on December 2, 2010.

~~Mr.~~SHENZHEN, China, September ~~Charles~~28, ~~Wang~~2010 is(BUSINESS ~~expected~~WIRE) to— ~~stay~~Tongjitang ~~with~~Chinese Medicines Company (the “Company” or “Tongjitang”) (NYSE: TCM), a leading specialty pharmaceutical company ~~until~~focusing ~~December.~~on ~~The~~the development, manufacturing, marketing and selling of modernized traditional Chinese medicine in China, today announced that the Company has ~~commenced~~entered aninto a share transfer agreement with Guizhou ~~executive~~Huixian ~~search~~Investment inManagement ~~order~~Company Limited (the “Buyer”) to ~~find~~sell 100% of the equity interest in Guizhou Tongjitang Asset Management Company Limited (the “Asset Management Co.”), which holds Guizhou Tongjitang Pharmaceutical Distribution Co., Ltd., Guizhou Tongjitang Pharmacy Chain Stores Co., Ltd. and a ~~replacement~~95% equity interest in Gui Liquor Co., Ltd. (“Gui Liquor”), for a total cash consideration of RMB259.3 million. Additionally, the Buyer will release Guizhou Tongjitang Pharmaceutical Co. Ltd. (“Tongjitang Pharmaceutical”), the Company’s wholly owned subsidiary, from its obligation to guarantee RMB105.0 million of Gui Liquor’s bank loans.

~~Xiaochun~~Pursuant ~~Wang~~to the share transfer agreement, ~~Tongjitang’s~~the ~~Chief~~purchase ~~Executive~~price ~~Officer~~will be payable in four installments of 5%, 5%, 45% and ~~Chairman~~45%, respectively. As of the ~~Board~~date of ~~Directors,~~this ~~stated~~announcement, the Company has ~~“On~~received ~~behalf~~the first installment of RMB13.0 million from the ~~Board,~~Buyer. ~~management,~~The ~~and~~Buyer ~~employees~~will be entitled to conduct due diligence within 60 days of ~~our~~the ~~company~~first payment, ~~I’d~~after ~~like~~which toall ~~thank~~parties ~~Mr. Charles~~involved will ~~Wang~~work ~~for~~together ~~his~~to ~~dedication~~obtain the approval and ~~contribution~~amend tothe ~~Tongjitang~~registration ~~over~~in order to change the ~~past~~shareholder of ~~two~~Asset ~~years~~Management ~~and~~Co. ~~wish~~to ~~him~~the ~~all~~Buyer. The second installment of the consideration will become ~~best~~payable onwithin ~~his~~seven ~~future~~days ~~endeavors~~after the completion of the amendment to the registration.”

Within 15 days after completing the amendment to the registration, the Buyer will be obligated to release Guizhou Tongjitang from its obligation to guarantee RMB105.0 million of Gui Liquor’s bank loans. The third and fourth installments of the consideration will be due June 30, 2011 and December 31, 2011, respectively, subject to the satisfaction of certain conditions.

Xiaochun Wang, Tongjitang’s Chief Executive Officer and Chairman of the Board of Directors, stated, “We have undertaken this major strategic move in order to better capitalize on China’s ongoing healthcare reform. After the transaction, Tongjitang will be better equipped to focus on its core business of developing, manufacturing and marketing modernised traditional Chinese medicines. We expect our profit margins to further improve after the sale of the least profitable component of our business.”

About Tongjitang Chinese Medicines Company

Tongjitang Chinese Medicines Company, through its operating subsidiaries ~~Tongjitang~~Guizhou ~~Pharmaceutical,~~ Tongjitang Pharmaceutical ~~Distribution,~~Co. ~~Tongjitang Chain Stores~~Ltd., Guizhou Long-Life Pharmaceutical Company Limited, Qinghai Pulante Pharmaceutical Co., Ltd. and Anhui Jingfang ~~and~~Pharmaceutical ~~Gui~~Co., ~~Liquor~~ Ltd., is a vertically integrated ~~specialty~~ specialty pharmaceutical company focused on the development, manufacturing, marketing and selling of of modernized traditional Chinese medicine in China. Tongjitang’s principal executive offices are located in Shenzhen, China.

Tongjitang’s flagship product, Xianling Gubao, is the leading traditional Chinese medicine for the treatment of osteoporosis in China as measured by sales in Renminbi. In addition to Xianling Gubao, the Company manufactures and markets 35 other modernized traditional Chinese medicine products and 36 western medicines. Please visit www.tongjitang.com for more information.

Safe Harbour Statement

This announcement contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations, assumptions, estimates and projections about the Company and the industry. Information regarding these risks, uncertainties and other factors is included in the Company’s most recent annual report on Form 20-F and other filings with the SEC. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward looking statements are reasonable, they cannot assure you that their expectations will turn out to be correct, and investors are cautioned that actual results may differ materially from the anticipated results.

CONTACT

ICR, Inc.
Ashley M. Ammon or Christine Duan
203-682-8200 (Investor Relations)

Filing Compare · TONGJITANG CHINESE MEDICINES CO